Relationship between metalloprotease expression in tumour and stromal cells and aggressive behaviour in prostate carcinoma: Simultaneous high-throughput study of multiple metalloproteases and their inhibitors using tissue array analysis of radical prostatectomy samples

Scandinavian Journal of Urology and Nephrology

Volumn 45, Issue 3, 2011, Pages 171-176

  Fernandez Gomez, Jesus ^a   Escaf, Safwan ^b   Gonzalez, Luis Ovidio ^b   Suarez, Aurelio ^b   Gonzalez Reyes, Salome ^b   González, Jose ^b   Miranda, Oscar ^a   Vizoso, Francisco ^b  

^a HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^b HOSPITAL DE JOVE   (Spain)

Author keywords

Gleason score; metalloproteases; prostate carcinoma; PSA; tissue array

Indexed keywords

COLLAGENASE 3; GELATINASE A; GELATINASE B; INTERSTITIAL COLLAGENASE; MATRILYSIN; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE 14; PROSTATE SPECIFIC ANTIGEN; STROMELYSIN 3; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TISSUE INHIBITOR OF METALLOPROTEINASE 3;

ADULT; AGED; ARTICLE; CANCER CELL; CANCER INVASION; CANCER TISSUE; CONTROLLED STUDY; DISEASE SEVERITY; FIBROBLAST; HIGH THROUGHPUT SCREENING; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; MALE; MONONUCLEAR CELL; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROSTATE SPECIFIC ANTIGEN BLOOD LEVEL; PROSTATECTOMY; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; STROMA CELL; TISSUE MICROARRAY;

ADULT; AGED; CARCINOMA; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; MALE; METALLOPROTEASES; MIDDLE AGED; PROSTATECTOMY; PROSTATIC NEOPLASMS; STROMAL CELLS; TISSUE ARRAY ANALYSIS; TISSUE INHIBITOR OF METALLOPROTEINASES;

EID: 79952761843     PISSN: 00365599     EISSN: 16512065     Source Type: Journal    
DOI: 10.3109/00365599.2010.545074     Document Type: Article

References (30)

1. Kirby RS, Partin A, Parsons JK, Feneley M. Treatment methods for early and advanced prostate cancer. New York: Informa HealthCare; 2008. p 107-14.
2. Hughes C, Murphy A, Martin C, Sheils O, O'Leary J. Molecular pathology of prostate cancer. J Clin Pathol 2005;58:673-84. (Pubitemid 40956818)
3. Demers M, Couillard J, Belanger S, St-Pierre Y. New roles for matrix metalloproteinases in metastasis. Crit Rev Immunol 2005;25:493-523. (Pubitemid 44268954)
4. Noe V, Fingleton B, Jacobs K, Crawford HC, Vermeulen S, Steelant W, et al. Release of an invasion promoter E-cadherin fragment by matrilysin and stromelysin-1. J Cell Sci 2001;114:111-18. (Pubitemid 32120080)
5. Cunya GR, Hayward SW, Wang YZ, Ricke WA. Role of the stromal microenvironment in carcinogenesis of the prostate. Int J Cancer 2003;107:1-10. (Pubitemid 37100079)
6. Kramer G, Mitteregger D, Marberger M. Is benign prostatic hyperplasia (BPH) an immune inflammatory disease? Eur Urol 2007;51:1202-16.
7. Gross-Goupil M, Massard C, Fizazi K. Integrating molecular oncology into therapeutic strategies for prostate cancer. Eur Urol Suppl 2009;8:114-19.
8. Wilson TJ, Singh RK. Proteases as modulators of tumour-stromal interaction: primary tumours to bone metastases. Biochim Biophys Acta 2008;1785:85-95.
9. Brehmer B, Biesterfeld S, Jakse G. Expression of matrix metalloproteinases (MMP-2 and -9) and their inhibitors (TIMP-1 and -2) in prostate cancer tissue. Prostate Cancer Prostatic Dis 2003; 6:217-22. (Pubitemid 37185149)
10. Pang ST, Flores-Morales A, Skoog L, Chuan YC, Nordstedt G, Pousette A. Regulation of matrix metalloproteinase 13 expression by androgen in prostate cancer. Oncol Rep 2004;11:1187-92.
11. Zhang L, Shi J, Feng J, Klocker H, Lee C, Zhang J. Type IV collagenase (matrix metalloproteinase-2 and -9) in prostate cancer. Prostate Cancer Prostatic Dis 2004;7:327-32. (Pubitemid 41721791)
12. Cao J, Chiarelli C, Richman O, Zarrabi K, Kozarekar P, Zucker S. Membrane type 1 matrix metalloproteinase induces epithelial-to-mesenchymal transition in prostate cancer. J Biol Chem 2008;283:6232-40.
13. Trudel D, Fradet Y, Meyer F, Harel F, Tetu B. Significance of MMP-2 expression in prostate cancer: an immunohistochemical study. Cancer Res 2003;63:8511-15. (Pubitemid 37549509)
14. Flemming ID, Cooper IS, Hemson DE. The 1992 TNM classification. American Joint Committtee on Cancer Staging Manual, 5th ed. Philadelphia, PA: JB Lippincott; 1997. p 219-22.
15. Whitmore W. Hormone therapy in prostatic cancer. Human Pathol 1956;21:273-9.
16. Parker RL, Huntsman DG, Lesack DW, Cupples JB, Grant DR, Akbari M, et al. Assessment of interlaboratory variation in the immunohistochemical determination of estrogen receptor status using a breast cancer tissue microarray. Am J Clin Pathol 2002;117:723-8. (Pubitemid 34457006)
17. Liotta LA, Kohn EC. The microenvironment of the tumour-host interface. Nature 2001;411:375-9.
18. Hara T, Miyazaki H, Lee A, Tran CP, Reiter RE. Androgen receptor and invasion in prostate cancer. Cancer Res 2008;68:1128-35. (Pubitemid 351272231)
19. Mylona E, Kapranou A, Mavrommatis J, Markaki S, Keramopoulos A, Nakopoulou L. The multifunctional role of the immunohistochemical expression of MMP-7 in invasive breast cancer. APMIS 2005, 113:246-55. (Pubitemid 40676805)
20. Abdel-Ghany M, Cheng HC, Elble RC, Pauli BU. The breast cancer beta 4 integrin and endothelial human CLCA2 mediate lung metastasis. J Biol Chem 2001;276:25438-46.
21. Davies G, Jiang WG, Mason MD. Matrilysin mediates extracellular cleavage of E-cadherin from prostate cancer cells: a key mechanism in hepatocyte growth factor/scatter factor-induced cell-cell dissociation and in vitro invasion. Clin Cancer Res 2001;7:3289-97. (Pubitemid 32963856)
22. Jiang Y, Goldberg ID, Shi YE. Complex roles of tissue inhibitors of metalloproteinases in cancer. Oncogene 2002;21:2245-52. (Pubitemid 34311378)
23. Wang F, Reierstad S, Fishman DA. Matrilysin over-expression in MCF-7 cells enhances cellular invasiveness and pro-gelatinase activation. Cancer Lett 2006;236:292-301.
24. Vizoso FJ, Gonzalez LO, Corte MD, Rodriguez JC, Vazquez J, Lamelas ML, et al. Study of matrix metalloproteinases and their inhibitors in breast cancer. Br J Cancer 2007;96:903-11. (Pubitemid 46452295)
25. Freije JM, Diez-Itza I, Balbin M, Sanchez LM, Blasco R, Tolivia J, et al. Molecular cloning and expression of collagenase-3, a novel human matrix metalloproteinase produced by breast carcinomas. J Biol Chem 1994;269:16766-73. (Pubitemid 24200439)
26. Knauper V, Cowell S, Smith B, Lopez-Otin C, O'shea M, Morris H, et al. The role of the C-terminal domain of human collagenase-3 (MMP-13) in the activation of procollagenase-3, substrate specificity, and tissue inhibitor of metalloproteinase interaction. J Biol Chem 1997;272:7608-16. (Pubitemid 27137308)
27. Chesler L, Golde DW, Bersch N, Johnson MD. Metalloproteinase inhibition and erythroid potentiation are independent activities of tissue inhibitor of metalloproteinases-1. Blood 1995;86:4506-15.
28. Luparello C, Avanzato G, Carella C, Pucci-Minafra I. Tissue inhibitor of metalloprotease (TIMP)-1 and proliferative behaviour of clonal breast cancer cells. Breast Cancer Res Treat 1999;54:235-44. (Pubitemid 29322346)
29. Wurtz SO, Schrohl AS, Sorensen NM, Lademann U, Christensen IJ, Mouridsen H, et al. Tissue inhibitor of metalloproteinases-1 in breast cancer. Endocr Relat Cancer 2005;12:215-27. (Pubitemid 40903085)
30. Yoshiji H, Harris SR, Raso E, Gomez DE, Lindsay CK, Shibuya M, et al. Mammary carcinoma cells over-expressing tissue inhibitor of metalloproteinases-1 show enhanced vascular endothelial growth factor expression. Int J Cancer 1998;75:81-7. (Pubitemid 28113981)